curis inc (CRIS:NASDAQ GM)
As of 8:10 PM 05/17/13 All times are local (Market data is delayed by at least 15 minutes).
Audit Committee* - curis inc (CRIS)
| Name (Connections) | Board Relationships | Title | Key Developments |
| James McNab Jr., MBA | 20 Relationships | Chairman and Member of Audit Committee | Curis Inc. announced delayed 10-Q filing 11/10/05 |
| Martyn Greenacre MBA | 64 Relationships | Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance Committee | Curis Inc. announced delayed annual 10-K filing 03/17/06 |
| Marc Rubin M. D. | 30 Relationships | Director, Member of Nominating & Corporate Governance Committee, Member of Audit Committee and Member of Science & Technology Committee | Curis Inc. to Restate Earnings Results for the Full Year Ended December 31, 2003, Nine Months Ended September 30, 2004 and 2005, First, Second and Third Quarters of 2005 03/17/06 |
Nominating Committee* - curis inc (CRIS)
| Name (Connections) | Board Relationships | Title | Key Developments |
| Martyn Greenacre MBA | 64 Relationships | Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance Committee | Curis, Inc. Announces Appointment of Kenneth Pienta to Board of Directors 03/11/13 |
| Kenneth Kaitin Ph.D. | 26 Relationships | Director, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee | Curis, Inc. Appoints Ali Fattaey, as President and Chief Operating Officer 02/19/13 |
| Marc Rubin M. D. | 30 Relationships | Director, Member of Nominating & Corporate Governance Committee, Member of Audit Committee and Member of Science & Technology Committee | Changgeng Qian to Step Down as Senior Vice President, Discovery and Preclinical Development of Curis Inc. on or About February 15, 2012 02/8/12 |
Advisory Committee* - curis inc (CRIS)
| Name (Board Relationships)/Title | Board Affiliations | ||
Member of Clinical Advisory Board | No other board affiliations | ||
Chairman of Clinical Advisory Board, Chairman of Scientific Advisory Board and Director | No other board affiliations |
*Data is at least as current as the most recent Definitive Proxy.
| Recently Viewed | |||
| CRIS:US | $4.12 USD | +0.11 |  |
| Company | Last | Change |
| Arqule Inc | $2.80 USD | +0.02 |
| Cell Therapeutics Inc | $1.16 USD | +0.01 |
| Cytokinetics Inc | $1.20 USD | +0.01 |
| Immunomedics Inc | $3.14 USD | +0.03 |
| Navidea Biopharmaceuticals Inc | $2.39 USD | +0.04 |
| View Industry Companies | ||
Industry Analysis
CRIS
Industry Average
| Valuation | CRIS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 42.9x |
|
| Price/Book | 10.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 32.4x |
|
Post a JobJobs
Sponsored Financial Commentaries
Sponsored Links
Report Data Issue
To contact CURIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Please enter your information in the following field(s):
Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
